Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Banc of California, Inc. stock logo
BANC
Banc of California
$14.97
-1.1%
$14.09
$11.52
$18.08
$2.21B0.672.29 million shs1.53 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$1.15
-0.9%
$1.20
$0.66
$5.92
$131.79M2.182.21 million shs1.04 million shs
Meritor, Inc. stock logo
MTOR
Meritor
$36.50
$36.40
$20.50
$36.50
$2.59B1.471.34 million shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Banc of California, Inc. stock logo
BANC
Banc of California
0.00%+1.39%+9.88%+18.30%+9.96%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
0.00%+0.44%-9.80%+24.42%-68.14%
Meritor, Inc. stock logo
MTOR
Meritor
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Banc of California, Inc. stock logo
BANC
Banc of California
4.8756 of 5 stars
3.32.02.53.31.53.33.1
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
3.5553 of 5 stars
3.11.00.04.71.41.70.6
Meritor, Inc. stock logo
MTOR
Meritor
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Banc of California, Inc. stock logo
BANC
Banc of California
2.67
Moderate Buy$17.3315.83% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.13
Hold$3.83233.33% Upside
Meritor, Inc. stock logo
MTOR
Meritor
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest FATE, BANC, and MTOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Banc of California, Inc. stock logo
BANC
Banc of California
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$18.00 ➝ $19.00
7/1/2025
Banc of California, Inc. stock logo
BANC
Banc of California
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$15.00 ➝ $16.00
6/12/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/21/2025
Banc of California, Inc. stock logo
BANC
Banc of California
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$18.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/28/2025
Banc of California, Inc. stock logo
BANC
Banc of California
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $15.00
4/28/2025
Banc of California, Inc. stock logo
BANC
Banc of California
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$15.00 ➝ $15.00
4/25/2025
Banc of California, Inc. stock logo
BANC
Banc of California
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Banc of California, Inc. stock logo
BANC
Banc of California
$1.89B1.17$1.28 per share11.72$17.80 per share0.84
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$13.63M9.67N/AN/A$2.80 per share0.41
Meritor, Inc. stock logo
MTOR
Meritor
$3.83B0.67$4.25 per share8.59$8.77 per share4.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Banc of California, Inc. stock logo
BANC
Banc of California
$126.89M$0.6523.029.07N/A8.23%6.30%0.55%7/23/2025 (Confirmed)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$186.26M-$1.49N/AN/AN/A-1,318.93%-47.17%-34.60%8/12/2025 (Estimated)
Meritor, Inc. stock logo
MTOR
Meritor
$199M$3.5110.408.110.595.84%39.69%8.41%N/A

Latest FATE, BANC, and MTOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025N/A
Banc of California, Inc. stock logo
BANC
Banc of California
$0.28N/AN/AN/A$278.43 millionN/A
5/13/2025Q1 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million
4/23/2025Q1 2025
Banc of California, Inc. stock logo
BANC
Banc of California
$0.24$0.26+$0.02$0.26$272.36 million$266.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Banc of California, Inc. stock logo
BANC
Banc of California
$0.402.67%N/A61.54%N/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Meritor, Inc. stock logo
MTOR
Meritor
N/AN/AN/AN/AN/A

Latest FATE, BANC, and MTOR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/9/2025
Banc of California, Inc. stock logo
BANC
Banc of California
quarterly$0.102.9%6/16/20256/16/20257/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Banc of California, Inc. stock logo
BANC
Banc of California
0.31
0.90
0.89
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.81
8.81
Meritor, Inc. stock logo
MTOR
Meritor
1.42
1.40
0.79

Institutional Ownership

CompanyInstitutional Ownership
Banc of California, Inc. stock logo
BANC
Banc of California
86.88%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Meritor, Inc. stock logo
MTOR
Meritor
96.26%

Insider Ownership

CompanyInsider Ownership
Banc of California, Inc. stock logo
BANC
Banc of California
2.69%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
5.51%
Meritor, Inc. stock logo
MTOR
Meritor
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Banc of California, Inc. stock logo
BANC
Banc of California
1,903147.62 million143.65 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550114.60 million108.29 millionOptionable
Meritor, Inc. stock logo
MTOR
Meritor
9,60070.86 million69.58 millionOptionable

Recent News About These Companies

Meritor Stock Price History
Automotive Axles rallies on inking MoU with Meritor HVS India
Meritor opens office at Redditch's Grosvenor House
Expert Reviews in Molecular Medicine
From HDAW: Cummins-Meritor Gives Aftermarket Strategy Update
Cummins-Meritor to relaunch management system
Meritor Stock Hits New 52-Week Low (MTOR)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Banc of California stock logo

Banc of California NYSE:BANC

$14.96 -0.17 (-1.09%)
Closing price 07/11/2025 03:58 PM Eastern
Extended Trading
$14.97 +0.01 (+0.04%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Banc of California, Inc. operates as the bank holding company for Banc of California that provides various banking products and services in California. The company offers deposit products, such as checking, savings, money market, demand, and time deposits; certificates of deposit; retirement accounts; and safe deposit boxes. It also provides real estate loans to professional developers and real estate investors for the acquisition, construction, refinancing, renovation, and on-going operation of commercial real estate properties; commercial real estate mortgage, residential real estate mortgage, and real estate construction and land loans; commercial loans and leases, such as equipment finance, other asset-based, venture capital, secured business, warehouse, and other lending services; small business administration loans; and consumer loans comprising personal, auto, and other loans, as well as home equity and revolving lines of credit. In addition, the company offers international banking, multi-state deposit, and asset and investment management services, as well as cash and treasury management services; and online, mobile, remote deposit, and telephone banking services. It serves small and middle-market businesses, venture capital firms, non-profit organizations, business owners, entrepreneurs, professionals, and high-net worth individuals. Banc of California, Inc. was founded in 1941 and is headquartered in Los Angeles, California.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$1.15 -0.01 (-0.86%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.18 +0.03 (+2.17%)
As of 05:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Meritor stock logo

Meritor NYSE:MTOR

Meritor, Inc. designs, develops, manufactures, markets, distributes, sells, services, and supports integrated systems, modules, and components in North America, South America, Europe, and the Asia Pacific. It operates through two segments, Commercial Truck, and Aftermarket and Industrial. The company offers axles, including front steer and rear drive axles for medium- and heavy-duty commercial vehicles; heavy-duty trailer axles; suspension modules and brake products comprising drum and disc brakes; universal joints and driveline components; trailer air suspension systems and products; transfer cases and drivelines; and advanced suspension modules for use in light-, medium- and heavy-duty military tactical wheeled vehicles. It also provides air brakes, such as cam drum, wedge drum, and air disc brakes, as well as wheel-end components, including hubs, drums, and rotors to medium- and heavy-duty commercial vehicle manufacturers; and electric drive systems comprising electric motors and inverters, power electronics, battery pack, electrified accessories, and related software and controls for terminal tractors and medium and heavy-duty trucks and buses. In addition, the company sells other complementary products, including third-party and private label items, which include brake shoes and friction materials; automatic slack adjusters; yokes and shafts; wheel-end hubs and drums; ABS and stability control systems; shock absorbers and air springs; and air brakes. Meritor, Inc. sells its products under the Meritor, Euclid, Trucktechnic, US Gear, AxleTech, and Mach brands primarily to original equipment manufacturers, their parts marketing operations, and their dealers, as well as other independent distributors and service garages in the aftermarket industry. The company was formerly known as ArvinMeritor, Inc. and changed its name to Meritor, Inc. in March 2011. Meritor, Inc. was founded in 1909 and is headquartered in Troy, Michigan.